Surrey Heartlands

Joint Formulary & PAD

Fluticasone with vilanterol (Relvar Ellipta) - Chronic Obstructive Pulmonary Disease (COPD)

You are here : Home > Formulary Search > Fluticasone with vilanterol (Relvar Ellipta) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Inhaler (dry powder)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :

Documentation

Guidelines (Local)
In-Check device for improving inhaler technique - Nov 16
Guidelines (Local)
COPD Primary Care Medicines Management Guidelines - updated Jun 23
Evidence Review
Relvar Ellipta COPD - Evidence review - Mar 2014
Webpage
How to use an Ellipta inhaler - video
Patient resource
How to use an Ellipta inhaler - Patient information leaflet

PAD Profile

ChemicalSubstance :
Fluticasone with vilanterol (Relvar Ellipta)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
ICS LABA
Keywords :
Chronic obstructive pulmonary disorder, ICS,
Brand Names Include :
Relvar Ellipta
Important Information :

Relvar Ellipta 92/22

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Chronic Obstructive Pulmonary Disease (COPD)
Supporting Documents :
5

Other Indications

Below are listed other indications that Fluticasone with vilanterol (Relvar Ellipta) is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (0)

  • No records returned.